Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Combat Meth Act Heads To Senate Floor Without Federal Preemption Clause

This article was originally published in The Tan Sheet

Executive Summary

The Senate Judiciary Committee unanimously passed the Combat Meth Act of 2005 (S 103) July 28 after adopting an amendment that strikes the federal preemption provision from the bill

You may also be interested in...



Trade Groups Make AER Legislation Wish List; Preemption Is Top Priority

Federal legislation requiring mandatory adverse event reporting for dietary supplements is both "likely" and "good" but must include preemption of state laws, trade groups asserted during a "State of the Industry" seminar Nov. 11 at SupplySide West in Las Vegas

Pseudoephedrine Sales Limit Provisions Attached To Patriot Act

The Talent/Feinstein Combat Meth Act (S 103) that would place behind-the-counter restrictions on pseudoephedrine was added to the Patriot Act reauthorization package in conference discussions Nov. 17

Trade Groups Make AER Legislation Wish List; Preemption Is Top Priority

Federal legislation requiring mandatory adverse event reporting for dietary supplements is both "likely" and "good" but must include preemption of state laws, trade groups asserted during a "State of the Industry" seminar Nov. 11 at SupplySide West in Las Vegas

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel